Business Context and Reporting Period
Company: ADVENTRX Pharmaceuticals, Inc. (Note: Request metadata listed "Savara Inc," but the filing text identifies the registrant as ADVENTRX Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: August 5, 2009
Event: Entry into a Material Definitive Agreement regarding a registered direct public offering of securities.
Key Financial Metrics and Transaction Details
- Securities Issued: 922 shares of 5% Series C Convertible Preferred Stock.
- Purchase Price: $1,000 per share of preferred stock.
- Gross Proceeds: Approximately $922,000 (922 shares x $1,000).
- Net Proceeds: Approximately $0.8 million after deducting placement agent fees and estimated offering expenses.
- Conversion Terms: Convertible into 7,092,307 shares of common stock at a price of $0.13 per share.
- Dividend: 5% cumulative dividend accruing until February 10, 2012.
- Make-Whole Provision: If converted prior to February 10, 2012, the company pays $125 per $1,000 of stated value (less dividends paid).
- Escrow: 12.5% of gross proceeds ($115,250) placed in escrow for dividend and make-whole payments.
- Placement Agent Fees: Approximately $64,540 (7.0% of gross proceeds) plus warrants.
- Warrants to Agent: Warrants to purchase up to 354,615 shares of common stock at an exercise price of $0.1625 per share.
Material Changes and Covenants
The filing details a significant capital raise and the imposition of restrictive covenants on the Company. Key changes and restrictions include:
- Capital Structure: Issuance of new preferred stock and potential dilution via conversion to over 7 million common shares.
- Restrictions on Company Actions: The agreement restricts the Company's ability to amend its charter, pay cash dividends on common stock, repurchase common stock, issue additional equity prior to August 25, 2009, or incur indebtedness without consent.
- Listing Requirement: The Company must use reasonable best efforts to maintain the listing of its common stock on specified U.S. securities exchanges.
- Redemption Triggers: The preferred stock may be redeemed upon material breach of contract, change in control, insolvency events, or delisting.
Outlook, Risks, and Unusual Items
- Closing Date: The transaction is expected to close on August 10, 2009, subject to customary conditions.
- Regulatory Status: Securities are being offered pursuant to an effective shelf registration statement (Form S-3, File No. 333-159376).
- Risk Factors: The filing highlights risks related to the Company's ability to maintain its stock exchange listing and the potential for dilution to existing shareholders upon conversion of the preferred stock.
- Financial Statements: This 8-K filing does not contain audited financial statements, revenue, profit, or cash flow data for the reporting period. It focuses solely on the transaction terms.
Investor Verification Checklist
- Verify the closing of the transaction on or around August 10, 2009.
- Confirm the actual net proceeds received after finalizing all offering expenses.
- Monitor the Company's compliance with the restrictive covenants, specifically regarding the issuance of additional equity before August 25, 2009.
- Track the Company's ability to maintain its stock exchange listing to avoid triggering redemption events.
- Review the impact of the 7,092,307 potential common shares on existing shareholder dilution.